Novo Nordisk A/S (STU:NOV) Net Income Including Noncontrolling Interests : €11,232 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Novo Nordisk A/S's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was €2,947 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was €11,232 Mil.

Novo Nordisk A/S Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Novo Nordisk A/S's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Net Income Including Noncontrolling Interests Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

5,214.40

5,663.97

6,422.27

7,463.53

11,227.44

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															1,827.00	2,661.93	2,609.47	3,014.14	2,946.70

Novo Nordisk A/S Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €11,232 Mil.

Novo Nordisk A/S Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (STU:NOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (STU:NOV) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.